A counterintuitive philosophy is gaining traction among healthcare strategists: building specialty drug networks that begin with a narrow, focused footprint rather than broad reach.
That argument was put forward by three industry voices on November 12, 2026, in the latest instalment of the Executive Conversations series.
Jon Hamrick, Rena Goins, and Bob Cochran joined the discussion for Episode 1, Part 3, addressing how specialty networks can be constructed more effectively from the ground up.
Their central contention was that starting small allows organisations to establish the foundational elements of a network before scaling, rather than expanding prematurely and creating structural weaknesses.
Specialty drug distribution has grown increasingly complex in recent years, with manufacturers, payers, and pharmacy partners all competing to shape how patients gain access to high-cost therapies.
The pressure to launch broadly and quickly is considerable, particularly as drug developers seek to demonstrate commercial viability to investors and demonstrate patient uptake to regulators.
Hamrick, Goins, and Cochran argued that this instinct to move fast and wide can undermine the long-term performance of a network, particularly when data infrastructure has not been properly established.
The trio identified three interlocking challenges that specialty network builders must balance simultaneously: access, data, and support, each of which can deteriorate if the network grows faster than its operational capacity.
Access, in this context, refers not simply to the number of pharmacies or providers in a network, but to whether patients can reliably and quickly obtain the medications they need through it.
Data capture and quality tend to suffer when networks expand too rapidly, making it harder for manufacturers and channel partners to understand where therapies are reaching patients and where gaps remain.
Support infrastructure, including patient services, prior authorisation assistance, and clinical coordination, also becomes strained when network growth outpaces the resources dedicated to sustaining it.
By contrast, a smaller initial network allows each of these three pillars to be properly stress-tested before additional complexity is introduced, according to the discussion.
The conversation forms part of a broader series examining how executives across the specialty pharmacy and market access space are rethinking conventional commercial strategies.
Specialty drugs, which typically carry high price tags and require careful handling or administration, represent one of the fastest-growing segments of pharmaceutical spending globally.
For manufacturers preparing launches in this space, the decisions made about network structure in the early months can have lasting consequences for both patient outcomes and commercial performance.
The episode with Hamrick, Goins, and Cochran suggests that patience in network construction, rather than aggressive early expansion, may be the more durable competitive advantage.